Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“The Pink Sheet” – Most Notable Stories Of 2012

Executive Summary

Developments in off-label enforcement and scrutiny of economic superiority claims, new approaches to R&D, and biosimilars are among issues that captured readers’ attention last year.

You may also be interested in...



Off-label Ruling’s Potential Fallout Is “Terrifying,” FDA’s Temple Says

If firms could promote drugs for uses not backed by well-controlled studies, it would be “a nightmare,” Temple says; AEI’s Scott Gottlieb suggests the agency might try to regulate how medicines are prescribed.

Biosimilar Meeting Requests Increase, But FDA Cancels Some For Lack Of Data

Some early meeting requests from potential biosimilar sponsors were not held because they did not include the necessary information for FDA to give development advice.

GSK Is Getting Ready For A Return To The ’90s

Though it has left behind the “industrialized” R&D approaches from the 1990s, Glaxo thinks its R&D revolution has produced strong growth that will get it back into major markets and maintain an output of three to five significant drug approvals per year. With that progress in sight, the firm is ready to transform its manufacturing and commercial model in the same way it recreated R&D.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS055021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel